Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats: Dose dependency

Pharmacological Reports

Volumn 58, Issue 4, 2006, Pages 533-539

  Rybczyńska, Apolonia ^a   Boblewski, Konrad ^a   Lehmann, Artur ^a   Orlewska, Czesława ^a   Foks, Henryk ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Blood pressure; Calcimimetics; Parathormone; Parathyroid hypertensive factor; Pharmacological parathyroidectomy

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM ION; INULIN; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PHOSPHATE; SODIUM CHLORIDE; THIOPENTAL; TRITIUM;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLADDER; BOLUS INJECTION; CALCIUM BLOOD LEVEL; CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG SYNTHESIS; GLOMERULUS FILTRATION RATE; INULIN CLEARANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PHOSPHATE URINE LEVEL; RAT; RAT STRAIN; URINARY EXCRETION;

EID: 33748656065     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Antonsen JE, Sherrard DJ, Andress DL: A calcimimetic agent acutely suspresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int, 1998, 53, 223-227.
2. 2+ sensing receptor from bovine parathyroid. Nature, 1993, 366, 575-580.
3. Chin JI, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J: Activation of the calcium receptor by the calcimimetics halts progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol, 2000, 11, 903-911.
4. Fiske CH and SubbaRow Y: The colorimetric determination of phosphorus. J Biol Chem, 1925, 66, 375-400.
5. Fox J, Lowe SH, Petty BA, Nemeth EF: NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther, 1999, 290, 473-479.
6. Goodman WG, Frazao JM, Goodkin DA, Turner GS, Liu W, Coburn JW: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int, 2000, 58, 436-445.
7. Goodman WG, Hladik DA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Bari YM et al.: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol, 2002, 13, 1017-1024.
8. Lewanczuk RZ, Resnick LM, Ho MS, Benishin CG, Shan J, Pang PKT: Clinical aspects of parathyroid hypertensive factor. J Hypertens, 1994, 12, 11-16.
9. Lewanczuk RZ, Wang J, Zhang ZR, Pang KT: Effects of spontaneously hypertensive rat plasma on blood pressure and tail artery calcium uptake in normotensive rats. Am J Hypertens, 1989, 2, 26-31.
10. Mukarami Y, Furuya Y, Wada M, Sakai T, Nagano N: Pharmacological properties of the calcimimetic compound NPS R-568 in vitro and in vivo. Clin Exp Nephrol, 2000, 4, 293-299.
11. Nemeth EF, Bennet SA: Tricking the parathyroid glands with novel calcimimetric agents. Nephrol Dial Transplant, 1999, 13, 1923-1925.
12. Ogata H, Ritz E, Odoni G, Amann K, Orth SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol, 2003, 14, 959-967.
13. Onsgaard-Meyer MJ, Berndt TJ, Khraibi AA, Knox FG: Phosphaturic effect of parathyroids hormone in the spontaneously hypertensive rats. Am J Physiol, 1994, 267, R78-R83.
14. 1H-NMR assay of the enantiomeric composition of amines and β-amino alkohols using O-acetyl mandelic acid as a chiral solvating agent. Tetrahedron, 1987, 43, 5451-5456.
15. Pattaragam A, Fox J, Alon US: Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int, 2004, 65, 1684-1689.
16. Rybczyńska A, Hoppe A, Knox FG: Propranolol restores phosphaturic effect of PTH in short-term phosphate deprivation. Am J Physiol, 1990, 258, R120-R123.
17. Silverberg SJ, Bone III HG, Mariott TB, Locker FG, Thys-Jacobs S, Dziem G et al.: Short-term inhibition of parathyroid hormone secretion by a calcium receptor agonist in patients with primary hyperparathyroidism. N Engl J Med, 1997, 337, 1506-1510.
18. Sutherland SK, Benishin CG: Regulation of parathyroid hypertensive factor secretion by Ca2+ in spontaneously hypertensive rat parathyroid cells. Am J Hypertens, 2004, 17, 266-272.
19. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N: NPS R-658 halts or reverses osteitis fibrosa in uremic rats. Kidney Int, 1998, 53, 448-453.
20. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int, 2000, 57, 50-58.
21. Yamazaki N, Atobe M, Kibayashi C: Nucleophilic addition of methyllithium to chiral oxime ethers: asymmetric preparation of 1-(aryl)ethylamines and application to a synthesis of calcimimetics (+)-NPS R-568 and its thio analog. Tetrahedron Lett, 2001, 42, 5029-5032.